Alnylam Pharmaceuticals (ALNY) Change in Account Payables (2009 - 2019)

Alnylam Pharmaceuticals (ALNY) has reported Change in Account Payables for 11 consecutive years, with -$30.1 million the latest figure, recorded in Q3 2019.

• For the quarter ending Q3 2019, Change in Account Payables fell 431.18% year-over-year to -$30.1 million; the trailing twelve-month figure through Sep 2019 stood at $12.4 million (up 6.22% YoY), and the FY2018 full-year result was $15.5 million, up 413.38% from the prior year.
• Change in Account Payables eased to -$30.1 million in Q3 2019 per ALNY's latest filing, from $43.5 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $43.5 million in Q2 2019 and bottomed at -$30.1 million in Q3 2019.
• Historically, Change in Account Payables has averaged $978631.6 across 5 years, with a median of $347000.0 in 2016.
• The sharpest annual moves came in 2017 and 2019: Change in Account Payables sank 3289.34% in 2017, then soared 6377.34% in 2019.
• Over 5 years, Change in Account Payables stood at $2.6 million in 2015, then surged by 351.39% to $11.6 million in 2016, then advanced by 6.68% to $12.3 million in 2017, then surged by 30.78% to $16.1 million in 2018, then tumbled by 286.56% to -$30.1 million in 2019.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$30.1 million, $43.5 million, and -$17.1 million for Q3 2019, Q2 2019, and Q1 2019 respectively.